Answers are grounded in this paper and cite their sources.
Ann Oncol 2017; 28(7): 1631–1639 (doi: 10.1093/annonc/mdx176) The following funding information has been added: “This work was supported in part by The University of Texas MD Anderson Cancer Center Support Grant P30 CA016672.” Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 studyAnnals of OncologyVol. 28Issue 7PreviewPrevious analysis of COMBI-d (NCT01584648) demonstrated improved progression-free survival (PFS) and overall survival (OS) with combination dabrafenib and trametinib versus dabrafenib monotherapy in BRAF V600E/K-mutant metastatic melanoma. This study was continued to assess 3-year landmark efficacy and safety after ≥36-month follow-up for all living patients.
No takes yet. Share an insight, caveat, or question.
Long et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: